2023 · FINDING
CITEDPhase 2 Obesity Trial
14.7% weight loss at 36 weeks with once-daily oral dosing
⚠ RESEARCH USE ONLY · NOT FDA-APPROVED FOR HUMAN USE · NOT MEDICAL ADVICE
WEIGHT LOSSPHASE 3 TRIALS
Orforglipron.
The Future of Weight Loss - No Injections
AKA · LY3502970 · Oral GLP-1
WEIGHT LOSSORAL
Once-daily oral GLP-1 pill - no injections needed. The future of weight loss drugs. Currently in Phase 3 trials with ~15% weight loss in Phase 2.
~25 hours (enables once-daily dosing)
Half-life
3
Citations
1
Routes
1
Categories
Store
Storage
70
Popularity
AT A GLANCE.
§ 01 · TL;DRTHE QUICK READ.
Once-daily oral GLP-1 pill - no injections needed. The future of weight loss drugs. Currently in Phase 3 trials with ~15% weight loss in Phase 2.
Orforglipron is a small molecule (not a peptide) that activates the same GLP-1 receptors as semaglutide. Because it's not a peptide, it survives digestion and can be taken as a simple daily pill - no injections or special timing required.
Not yet approved - Phase 3 trials ongoing. Dose titration likely required.
WHAT IT MIGHT HELP WITH.
1
Significant weight loss (~15% in Phase 2)
2
No injections required
3
No empty stomach/timing requirements
4
Daily pill convenience
5
Potentially lower cost than peptide GLP-1s
HOW IT WORKS.
§ 02 · MECHANISMOrforglipron is a small molecule (not a peptide) that activates the same GLP-1 receptors as semaglutide. Because it's not a peptide, it survives digestion and can be taken as a simple daily pill - no injections or special timing required.
Non-peptide small molecule GLP-1 receptor agonist. Unlike semaglutide (a peptide requiring special absorption enhancers), orforglipron is a small molecule that survives gastrointestinal transit intact. Activates GLP-1 receptors to reduce appetite, slow gastric emptying, and improve glucose homeostasis. Once-daily oral dosing with no food restrictions.
WHO IT'S FOR
- ✓Those who want GLP-1 benefits without injections
- ✓People with needle phobia
- ✓Those seeking convenience over injectable options
- ✓Future patients once FDA approved
WHO SHOULD AVOID
- ✕Those needing treatment now (not yet approved)
- ✕History of medullary thyroid carcinoma
- ✕MEN 2 syndrome
- ✕Severe GI conditions
DOSING PROTOCOL.
§ 04 · DOSINGTYPICAL RANGE
Not yet approved - Phase 3 trials ongoing. Dose titration likely required.
Up to 45mg once daily (Phase 3 doses)
FREQUENCY
Most-cited schedule
Once daily, any time, with or without food
ROUTES
Delivery methods
ORAL
HALF-LIFE
Steady state drives frequency
~25 hours (enables once-daily dosing)
STORAGE
Protect from light, refrigerate
Store at controlled
⚠ NOTE
These are reported protocols from research literature and practitioner accounts, not prescriptions. No FDA-approved human dose exists for research compounds. Anyone using Orforglipron should work with a qualified physician and source from a supplier providing third-party COAs.
FORMS AVAILABLE
- · Oral tablet
⚠ RESEARCH INFORMATION ONLY · NOT MEDICAL ADVICE
SIDE EFFECTS & RISKS.
§ 06 · SAFETY•
Nausea
Common · moderate
Similar to injectable GLP-1s
·
Vomiting
Occasional · mild
·
Diarrhea
Common · mild
·
Decreased appetite
Very common · mild
This is kind of the point
WHERE TO SOURCE
§ 07 · SUPPLIERPEAK LAB
PEPTIDES
PEPTIDES
SUPPLIER OF RECORD · 12 BATCHES PASSED
Orforglipron is not currently stocked by our vetted supplier. If you're researching it, verify any source with a third-party COA — our full sourcing guide covers what to look for.
COMMON QUESTIONS.
§ 08 · FAQHow is orforglipron different from Rybelsus (oral semaglutide)?
Rybelsus is still a peptide requiring empty stomach dosing and absorption enhancers. Orforglipron is a small molecule - take it anytime with or without food. Much simpler and potentially cheaper to manufacture.
When will orforglipron be available?
Phase 3 trials are ongoing with Eli Lilly. If successful, FDA approval could come in 2025-2026. It would be a game-changer for oral weight loss medication.
Is orforglipron as effective as injectable semaglutide?
Phase 2 showed ~15% weight loss which is comparable to injectable GLP-1s. Phase 3 will confirm efficacy. The convenience of no injections could improve adherence and real-world results.
Why is an oral GLP-1 such a big deal?
Injectable GLP-1s require weekly shots, cold storage, and medical supplies. A daily pill is dramatically more convenient and could make GLP-1 therapy accessible to many more people who avoid injections.
MORE ON ORFORGLIPRON.
§ 10 · FIELD NOTES◆ Sourcing
Compounded Semaglutide In 2026: What Changed, What's Next
The FDA removed semaglutide from shortage in early 2025. Compounding pharmacies scrambled. Legal battles followed. Here is what actually happened and what to do.
8 min·READ →
◆ Research Updates
Orforglipron: The First Oral Non-Peptide GLP-1, Coming 2026
Lilly's once-daily oral GLP-1 is under FDA review with a mid-2026 decision expected. It's not a peptide — and that's exactly the point.
7 min·READ →
◆ Research Updates
CagriSema: Novo's Answer to the Triple-Agonist Era
REDEFINE 1 showed 22.7% weight loss with the semaglutide + cagrilintide combo. Novo is filing for regulatory approval in 2026. Here is the case for and against it.
8 min·READ →
◆ THE PEPGAINS DISPATCH
GET THE NEXT UPDATE FIRST.
New research on Orforglipron + a weekly dispatch on everything else moving in the peptide world. One email. Unsubscribe in a click.